Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF SEVEN INNOVATIVE PRODUCTS INCLUDING MAZDUTIDE AND PECONDLE IN THE 2026 NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that seven innovative products of Innovent were successfully included in the updated 2026 National Reimbursement Drug List of China (the "**NRDL**").

Products included in the NRDL for the first time include mazdutide (a GCG/GLP-1 dual receptor agonist), PECONDLE® (picankibart injection, an IL-23p19 inhibitor), TABOSUN® (Ipilimumab N01 injection, a CTLA-4 inhibitor), and Vanflyta® (quizartinib, a Type II FLT3 inhibitor). Products with newly added indications included in the NRDL comprise TYVYT® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jaypirca® (pirtobrutinib tablets, a non-covalent BTK inhibitor); and SINTBILO® (tafolecimab injection, a fully human PCSK9 monoclonal antibody) was successfully renewed. The updated NRDL will officially take effect from January 1, 2027.

The Company is pleased that the seven innovative drugs of Innovent have been successfully included in the NRDL this time, covering disease areas with heavy societal burdens such as oncology (colon cancer, renal cancer, and hematological malignancies), cardiovascular and metabolic diseases, as well as autoimmune diseases. The inclusion of these innovative drugs in the NRDL will further enhance the accessibility and affordability for patients, allowing more general public to benefit. With this, the lineup of Innovent's innovative drugs covered by the NRDL has expanded to 17, cumulatively benefiting over 20 million patients, and continuously fortifying the medication safeguards for patients through innovative achievements. Adhering to our corporate mission to 'empower patients worldwide with affordable, high-quality biopharmaceuticals', Innovent consistently places patient needs at its core, actively responds to the strategic call of 'Healthy China 2030', facilitates the construction of a universal health safeguard system through practical actions, and promotes the continuous improvement of people's health. The Company will actively cooperate with the implementation of medical insurance policies, ensuring that high-quality innovative medicines benefit countless households faster and more broadly.

Mazdutide

Innovent entered into an exclusive license agreement with Eli Lilly and Company ("**Lilly**") for the development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists —such as promoting insulin secretion, lowering blood glucose and reducing body weight. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.

Mazdutide is newly included in the updated NRDL for: type 2 diabetes in adults. Mazdutide is the first and only approved GCG/GLP-1 dual receptor agonist globally. This inclusion into the NRDL will provide a better option for the comprehensive management of Chinese patients with type 2 diabetes.

PECONDLE® (picankibart injection)

Picankibart injection (IBI112) is a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody injection. It is a monoclonal antibody with independent intellectual property rights independently developed by Innovent, which specifically binds to the IL-23p19 subunit. By preventing IL-23 from binding to cell surface receptors, it blocks the IL-23 receptor-mediated signaling pathway to exert anti-inflammatory effects.

Picankibart injection is newly included in the updated NRDL for: adult patients with moderate to severe plaque psoriasis eligible for systemic therapy. Picankibart injection is the first and the only domestic IL-23p19 inhibitor. It is also the first product among global IL-23p19 drugs with the same target to achieve a PASI 90 response rate exceeding 80% at 16 weeks in a Phase III registrational clinical trial, and possesses the longest maintenance dosing interval in its class (once every 12 weeks). This inclusion into the NRDL will effectively improve treatment convenience and patient compliance.

TABOSUN® (Ipilimumab N01 injection)

Ipilimumab N01 (IBI310) is a recombinant fully human anti-CTLA-4 monoclonal antibody independently developed by Innovent. Ipilimumab N01 can specifically bind to CTLA-4, thereby blocking CTLA-4-mediated T cell inhibition, promoting the activation and proliferation of T cells, enhancing the tumor immune response, and achieving anti-tumor effects.

Ipilimumab N01 injection is newly included in the updated NRDL for: use in combination with sintilimab for the neoadjuvant treatment of patients with resectable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer. As the world's only approved dual-immunotherapy combination regimen for this indication, it synergistically activates anti-tumor immunity through both the CTLA-4 and PD-1 pathways, providing patients with a short-course, chemotherapy-free, and 0-recurrence neoadjuvant treatment option, which fills the dual gaps in clinical practice and the medical insurance coverage.

VANFLYTA® (quizartinib)

Quizartinib is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations, developed by Daiichi Sankyo and solely commercialized in Mainland China by Innovent.

Quizartinib is newly included in the updated NRDL for: newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive as detected by an adequate validated diagnostic test. It has effectively filled the gap in the NRDL coverage, addressed the shortcomings in clinical treatment, and practically alleviated the treatment burden of AML patients.

TYVYT® (sintilimab injection)

Sintilimab injection (IBI308) is an innovative PD-1 inhibitor drug jointly developed by Innovent and Eli Lilly and Company.

Sintilimab has been approved in China for ten indications, covering squamous non-small cell lung cancer, non-squamous non-small cell lung cancer (including EGFR/ALK wild type NSQ-NSCLC and EGFR-TKI treatment failure NSQ-NSCLC), hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma.

Two additional indications have been successfully included in the updated NRDL: sintilimab in combination with ipilimumab N01 as neoadjuvant treatment for patients with resectable stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer; and sintilimab in combination with fruquintinib for patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) therapy and have not received programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy in the first-line setting. The NRDL inclusion of two indications further broadens reimbursement coverage for the neoadjuvant treatment of patients with MSI-H/dMMR colon cancer and the combination treatment of targeted therapy and immunotherapy for second-line renal cell carcinoma patients.

Jaypirca® (pirtobrutinib tablets)

Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly and Company, for which Innovent is responsible for the exclusive commercialization in Mainland China. In preclinical studies, pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested[i]. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)[ii, iii].

Pirtobrutinib was approved in China in October 2024 and was officially included in the NRDL on January 1, 2026. One additional indication has now been successfully included in the updated NRDL: treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior systemic therapy that included a Bruton's tyrosine kinase (BTK) inhibitor. This further broadens NRDL coverage for the treatment of this disease.

SINTBILO® (tafolecimab injection)

Tafolecimab injection (IBI306) is the first domestic fully human anti-PCSK9 monoclonal antibody independently developed by Innovent. By inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) in blood plasma, it blocks its binding to the low-density lipoprotein receptor (LDLR), thereby preventing the endocytosis and degradation of LDLR, increasing the expression level and quantity of LDLR on the cell surface, enhancing the reuptake of low-density lipoprotein cholesterol (LDL-C) by LDLR, and decreasing the circulating LDL-C level, ultimately achieving the purpose of lowering blood lipids.

Tafolecimab was approved for marketing in August 2023, and was officially included in the NRDL on January 1, 2025. This successful contract renewal will further alleviate the financial burden on patients, enabling this advanced lipid-lowering therapy to benefit a broader patient population.

Looking towards the goals of the China's "15th Five-Year Plan", the Company will remain committed to innovation-driven development, focus on the unmet clinical needs in the field of major diseases, and continuously advance the research and development, manufacturing and commercialization of high-quality innovative drugs, to serve people's lives and health with more innovative achievements, and contribute to the high-quality development of the biopharmaceutical industry and the building of a healthy China.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
November 15, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Ms. Qian Zhang as Executive Director, Mr. Ronald Hao Xi Ede as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.

References

i Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5

ii Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1

iii Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7